Insights on Discovery
-
Production And Purification Of AAV At The 50 L Scale
12/4/2023
Explore data demonstrating the performance of a scalable system for AAV manufacturing that enables gene therapy researchers to utilize a single system throughout the entire development process.
-
High Efficiency T-Cell Editing
11/28/2023
Explore a modified synthetic sgRNA that allows you to achieve efficient, multigene knockout in primary human resting CD4+ T-Cells.
-
Navigating The Complexities Of Engagement Qualifications In Single-Use Assemblies
11/27/2023
In lieu of formal industry guidance for single-use integrators, it’s important to understand engagement testing, as well as review the factors related to the selection of retention device and assembly.
-
How Tunable Cell Processing Solutions Ensure Separation Efficiency
11/17/2023
Single-use tubular bowl centrifuges are standing out to cell therapy developers for their ability enable the optimal balance between high separation efficiency, high productivity, and low shear.
-
The Shear Problem Facing Cell Separation
11/17/2023
Explore the significance of low-shear separation and delve into the principles of tubular bowl centrifugation, comparing it to alternative technologies.
-
How Takeda Streamlines Assay Transfer And Troubleshooting
11/13/2023
When one of Takeda’s quality control facilities wanted to improve assay success rates by reducing liquid handling variability, they turned to the Artel MVS® to help their assay process.
-
Improving Automated Liquid Handling Performance For Serum-Based Assays
11/13/2023
Here, we highlight the similarities between the serum mimic solution Artel is developing and various commercially available sera as well as the importance of choosing the appropriate liquid classes.
-
How CRL Automated Their Assay And Scale Throughput
11/13/2023
Discover how Artel® technology played a critical role in Clinical Reference Labs' exceptionally fast development and scale-up of a saliva-based SARS-CoV-2 assay to meet the unprecedented testing need.
-
Discover A Reference Control Alternative To HIV+ Donor Samples
11/2/2023
A Fortune 100 pharmaceutical company found success in addressing their HIV treatment research challenges through a partnership that provided them with a p24-expressing, non-infectious synthetic T cell mimic.
-
Navigating The FDA’s Draft Guidance On Psychedelic Drug Development
11/2/2023
Uncover new guidance for the development of innovative therapies in the realm of mental health and addiction treatment.